Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
1999-08-30
2002-02-26
Yucel, Remy (Department: 1636)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
06350857
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses, In particular, in these and in other regards, the invention relates to polynucleotides and polypeptides of the ffh (Fifty-Four Homologue) family, hereinafter referred to as “ffh”.
BACKGROUND OF THE INVENTION
The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago,
Streptococcus pneumoniae
has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated an the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with
S. pneumoniae
, many questions Concerning the virulence of this microbe remain, It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics
The frequency of
Streptococcus pneumoniae
infections has risen dramatically in the past 20 years. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate
Streptococcus pneumoniae
strains which are resistant to some or all of the standard antibiotics. This has created a demand for both new antimicrobial agents and diagnostic tests for this organism.
Ffh, and homologues, are components of the protein secretary apparatus of bacteria and play an essential role in targeting of proteins to the cytoplasmic membrane (and possibly beyond). Ffh is the bacterial homologue of the 54 kDa sub-unit of the eukaryotic Signal Recognition Particle. Inhibition of function of the protein is injurious to bacterial cells.
Clearly, there is a need for factors such as the compounds of the invention, that have a present benefit of being useful to screen compounds for antibiotic activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists which can play a role in preventing ameliorating or correcting infections dysfunctions or diseases.
The polypeptides of the invention have amino acid sequence homology to a known ffh protein encoded by Streptococcus mutans (nucleotides 969 to 2519 of Genbank Entry Accession number U88582).
SUMMARY OF THE INVENTION
It is an object of the invention to provide polypeptides that have been identified as ffh polypeptides of the invention by homology between the amino acid sequence set out in Table 1 [SEQ ID NO: 2] and a known amino acid sequence or sequences of other proteins such as ffh protein, encoded by Streptococcus mutans.
It is a further object of the invention to provide polynucleotides that encode ffh polypeptides, particularly polynucleotides that encode the polypeptide herein designated ffh.
In a particularly preferred embodiment of the invention the polynucleotide comprises a region encoding ffh polypeptides comprising the sequence set out in Table 1 [SEQ ID NO:1], or a variant thereof.
In another particularly preferred embodiment of the invention there is a ffh protein from
Streptococcus pneumoniae
comprising the amino, acid sequence of Table 1 [SEQ ID NO:2], or a variant thereof.
In accordance with another aspect of the invention there is provided an isolated nucleic acid molecule encoding a mature polypeptide expressible by the
Streptococcus pneumoniae
0100993 strain contained in the deposited strain.
In further aspect of the invention there are provided isolated nucleic acid molecules encoding ffh, particularly
Streptococcus pneumoniae
ffh, including mRNAs, cDNAs, genomic DNAs, Further embodiments of the invention include biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
In accordance with another aspect of the invention, there is provided the use of a polynucleotide of the invention for therapeutic or prophylactic purposes, in particular genetic immunization. Among the particularly preferred embodiments of the invention are naturally occurring allelic variants of ffh and polypeptides encoded thereby.
Another aspect of the invention there at provided polypeptides of
Streptococcus pneumoniae
referred to herein as ffh as well as biologically, diagnostically, prophylactically, clinically or therapeutically useful variants thereof, and compositions comprising the same.
Among the particularly preferred embodiments of the invention are variants of ffh polypeptide encoded by naturally occurring alleles of the ffh gene.
In a preferred embodiment of the invention there are provided methods for producing the aforementioned ffh polypeptides.
In accordance with yet another aspect of the invention, there are provided inhibitors to such polypeptides, useful as antibacterial agents, including, for example, antibodies.
In accordance with certain preferred embodiments of the invention there are provided products, compositions and methods for assessing ffh expression, treating disease, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema ad endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid, assaying genetic variation and administering a ffh polypeptide or polynucleotide to an organism to raise an immunological response against a bacteria, especially
Streptococcus pneumoniae
bacteria.
In accordance with certain preferred embodiments of this and other aspects of to invention there are provided polynucleotides that hybridize to ffh polynucleotide sequences, particularly under stringent conditions.
In certain preferred embodiments of the invention there are provided antibodies against ffh polypeptides.
In other embodiments of the invention there are provided methods for identifying compounds which bind to or otherwise interact with and inhibit or activate an activity of a polypeptide or polynucleotide of the invention comprising: contacting a polypeptide or polynucleotide of the invention with a compound to be screened under conditions to permit binding to or other interaction between the compound and the polypeptide or polynucleotide to assess the binding to or other interaction with the compound such binding or interaction being associated with a second component capable of providing a detectable signal in response to the binding or interaction of the polypeptide or polynucleotide with the compound; and determining whether the compound binds to or otherwise interacts with and activates or inhibits an activity of the polypeptide or polynucleotide by detecting the presence or absence of a signal generated from the binding or interaction of he compound with the polypeptide or polynucleotide.
In accordance with yet another aspect of the invention, there are provided ffh agonists and antagonists, preferably bacteriostatic or bacteriocidal agonist and antagonists.
In a further aspect of the invention there are provided compositions comprising a ffh polypeptide or a ffh polypeptide for administration to a cell or to a multicellular organism.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.
GLOSSARY
The following definitions are provided to facilitate understanding of certain terms used frequently herein.
“Host cell” is a cell which has been transformed or transfected, or is capable of transformation or tra
Deibert Thomas S.
Gimmi Edward R.
King William T.
SmithKline Beecham Corp.
Yucel Remy
LandOfFree
Fifty-four homologue (ffh) from streptococcus pneumoniae does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fifty-four homologue (ffh) from streptococcus pneumoniae, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fifty-four homologue (ffh) from streptococcus pneumoniae will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2946549